NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) | Biotech Hunter

Enrollment

358

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 25, 2017

Study Completion Date

October 25, 2017

Conditions

Rhinitis, Allergic, Perennial and SeasonalRhinitis, Allergic

Interventions

DRUG

FFNS

FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.

OTHER

Placebo

Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.

Trial Locations (16)

100034

GSK Investigational Site, Beijing

200040

GSK Investigational Site, Shanghai

200092

GSK Investigational Site, Shanghai

200127

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

310052

GSK Investigational Site, Hangzhou

323027

GSK Investigational Site, Wenzhou

350025

GSK Investigational Site, Fuzhou

361003

GSK Investigational Site, Xiamen

400014

GSK Investigational Site, Chongqing

410005

GSK Investigational Site, Changsha

410011

GSK Investigational Site, Changsha

518038

GSK Investigational Site, Shenzhen

030016

GSK Investigational Site, Taiyuan

Unknown

GSK Investigational Site, Beijing

GSK Investigational Site, Changsha